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Abstract
Background and objective: Health-related quality of life (HRQL) in respiratory diseases has been generally
investigated in clinical settings, focusing on a single disorder. In this study on a general population sample,
we assessed the relationship between HRQL and several respiratory diseases studied simultaneously (COPD,
current (CA) and past (PA) asthma, allergic (AR) and non-allergic (NAR) rhinitis and chronic bronchitis (CB).
Methods: Controls (n = 328) and cases of NAR (n = 95), AR (n = 163), CB (n = 48), CA (n = 224), PA (n = 126)
and COPD (n = 28) were recruited in the centre of Verona in the frame of the Italian multi-case control GEIRD
(Gene Environment Interactions in Respiratory Diseases) study; HRQL was measured through the SF-36 questionnaire.
The relationships between HRQL (in terms of Physical (PCS) and Mental Component Scores (MCS)), respiratory diseases,
and covariates were evaluated.
Results: With respect to controls, the adjusted PCS median score was worse in subjects suffering from current asthma
(− 1.7; 95%CI:-2.8;-0.6), CB (− 3.8; 95%CI:-5.7;-1.9), and COPD (− 5.6; 95%CI:-8.1;-3.1). MCS was worse in current asthmatics
(− 2.2; 95%CI:-4.1;-0.3), CB (− 5.5; 95%CI:-8.7;-2.2), and COPD cases (− 4.6; 95%CI:-8.8;-0.5) as well.
Conclusions: To our knowledge, this is the first study in the general population that analyzed HRQL performing a
simultaneous comparison of HRLQ in several respiratory disorders. We found that subjects suffering from COPD, CA,
and CB had the poorest HRQL. Clinicians should carefully consider the possible impact of respiratory disorders as CB
and not only that of CA and COPD.
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Summary at a glance
We conducted a population-based study investigating
the differences in HRQL across the most common
chronic respiratory disorders. Unlike previous studies,
we were able to consider several diseases simultaneously
by using a multicase-control design. COPD, asthma and
chronic bronchitis showed worse physical and mental
SF-36 scores than controls.
Introduction
In chronic illnesses, Health-related Quality of Life
(HRQL, which daily activities people can perform and
how they feel) is a primary concern and is often used as
the outcome in both clinical trials and observational
studies [1]. In addition, as people generally seek health
care only when they feel unhealthy, self-perception of
health is a predictive of the future burden on the health
care delivery system [2, 3].
Asthma is a critical public health problem worldwide,
affecting people of all ages and both sexes [4, 5]. It im-
pairs school and work performance [6] as well as phys-
ical and mental quality of life [3, 4, 7].
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Chronic obstructive pulmonary disease (COPD) is char-
acterized by persistent airflow limitation, associated with an
enhanced chronic inflammatory response in the airways
and the lungs to noxious particles or gases. Frequently, pa-
tients suffering from COPD have impaired daily activities,
often in association with symptoms of dyspnea and fatigue
[8, 9]. Also subjects with chronic bronchitis (CB) may
present poor mental health [10–12]. Rhinitis is an inflam-
mation of the lining of the nose and is characterized by
nasal symptoms, including rhinorrhea, sneezing, nasal
blockage and/or itching of the nose [13]. Allergic rhinitis
(AR), a symptomatic disorder of the nose induced after al-
lergen exposure, may be associated with daily activities re-
duction [14]. In addition, having an allergic reaction could
cause significant fatigue and mood changes [15], impair-
ment of cognitive functions [16, 17] depression, and anxiety
[18, 19]. Although HRQL has been frequently assessed in
subjects with AR [15, 19], there is a lack of epidemiological
studies on non-allergic rhinitis (NAR) [20], especially on
the quality of life of people suffering from it.
Subjects suffering from AR commonly have current
asthma (CA) and the effect of AR alone cannot be disen-
tangled. Therefore, it can be of interest to analyse the
role of AR in subjects without asthma.
HRQL in respiratory diseases has been mainly investi-
gated in a clinical setting, where usually subjects have a
worse condition with respect to general population and, as
a consequence, present a HQRL that does not correspond
to real life [17, 20–22]. Moreover, most of previous studies
focused on a single disorder, losing the chance to analyze
the relative weight of the different respiratory disorders.
In the frame of the Gene Environment Interactions in
Respiratory Diseases (GEIRD) survey, a multicase-control
study in the general population, the aim of this paper was
to assess the relationship between HRQL and COPD,
asthma, CB, and rhinitis considered simultaneously.
Methods
The GEIRD project is an ongoing multicase-control
study, coordinated by the Verona centre, involving seven
Italian centres [23]. In the first stage of the study, new
random samples and pre-existing cohorts (the Italian
Study on Asthma in Young Adults (ISAYA) [24] and the
Italian arm of the European Community Respiratory
Health Survey (ECRHS) [25]) from the general popula-
tion (20–64 years, male/female = 1/1) were mailed a
screening questionnaire on respiratory symptoms (Fig. 1).
In particular, for the new random sample, 3000 subjects
aged 20–44 and 1000 subjects aged 45–64, male/females
=1/1, from the general population were selected. In the
second stage of GEIRD, on the basis of answers to the
screening questionnaire (Additional file 1 (a)), all prob-
able cases of asthma and COPD/ CB, a sample of prob-
able cases of AR (44%), other condition (39%), and
controls (61%), were invited to clinics to be phenotyped
[26]. During the clinical visit, each subject underwent a
computer-assisted clinical interview, lung function [27,
28] and allergological tests [29] (Additional file 1 (b)),
and the 36-item Short Form (SF-36) questionnaire. All
the protocols were in agreement with the international
guidelines and can be found on the GEIRD website
(www.geird.org) [30]. Ethical approval was obtained in
each centre from its appropriate ethics committee, and
written consent was obtained from each participant.
In this paper, only the data of the Verona centre were
considered, because the data collection was at an initial
stage in the other centres.
Quality of life questionnaire – The SF-36
As a part of the GEIRD core protocol, all the participants’
HRQL was assessed using SF-36 questionnaire version
1.6, which is a generic quality of life, self-administered
measure containing 36 items [27, 31]. Physical Compo-
nent Summary (PCS) and Mental Component Summary
(MCS) measures were calculated. Missing data were
treated as recommended in the SF-36 manual and inter-
pretation guide [28].
Identification of cases and controls in clinics
The subjects were hierarchically classified as follows:
Fig. 1 Timeline for the new random sample and the cohorts of the GEIRD study
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 28 cases of COPD (he/she had post-bronchodilator
FEV1/FVC < LLN or < 70%);
 224 cases of current asthma (“CA”, he/she reported
lifetime asthma; or he/she reported asthma-like
symptoms/medicines in the last 12 months and had
(1): a positive methacholine challenge test with
PD20 < 1mg or (2) pre-bronchodilator FEV1/FVC
< 70% or < LLN with a positive reversibility test (i.e.
FEV1 > 12% and > 200 mL after the administration
of 400 μg of salbutamol); all cases already defined
as COPD cases could not be defined as CA cases;
 126 cases of past asthma (“PA”, he/she reported
lifetime asthma but did not fulfil the criteria for
CA); all cases already defined as COPD cases could
not be defined as PA cases;
 48 cases of CB (he/she was not a COPD or CA/PA
case and he/she reported chronic cough or phlegm
(> 3 months/year for at least 2 years));
 163 cases of allergic rhinitis (AR) and 95 non-
allergic rhinitis (“NAR”) (he/she was not a COPD,
CA/PA, BC case and he/she had nasal allergies or
nasal problems in the presence of animal(s), pollens,
dust plus negative (NAR) or positive (AR) skin prick
test);
 328 controls (subjects without any nasal/respiratory
symptoms/conditions reported in the clinical
questionnaire neither in the clinic nor in the
screening questionnaire).
The Additional file 2 shows the details of this hier-
archical classification and the overlapping among cases.
Potential determinants of HRQL and covariates
The relationship between case-control status (COPD,
CA, PA, AR, NAR, CB and controls, the independent
variable) and HRQL (the dependent variable) was inves-
tigated. We took into account the following potential
confounders: gender, age (years), body mass index (BMI,
kg/m2), education level (low if a subject had completed
full-time education before the age of 16, high otherwise),
smoking habits (never smoker, past smoker = ever
smoker who did not smoke in the last month, current
smoker = subject who smoked in the last month), pres-
ence/absence of at least one non-respiratory comorbidity
(gastritis, stomach ulcer, gastroesophageal reflux, hiatal
hernia, esophagitis, osteoporosis, gout, arthritis, osteo-
arthritis, pulmonary embolism, diabetes, stroke, cancer),
presence/absence of at least one heart disease (heart at-
tack (coronary thrombosis), angina, arrhythmia, hyper-
tension and other heart problems).
The analyses were also adjusted for study sample/co-
hort (ECRHS Italy, ISAYA, new random sample) and
calendar period, which divided the study period into se-
mesters, starting from the beginning of stage 2 (April
2008). The latter covariate took into account both sea-
sonality (April to September, the “warm/hot” season in
Italy, compared to October to March, the “cool/cold”
season) and potential temporal trends.
Statistical analysis
Data were summarized as counts and percentages,
means (standard deviation (SD)) and medians (inter-
quartile difference (IQD)). The Chi-square and the
Kruskal-Wallis tests were used to investigate differences
in variables among respiratory conditions, where appro-
priate. As scores were not normally distributed, differ-
ences in the crude medians of PCS and MCS across
cases and controls were tested using the Kruskal-Wallis
test.
Quantile regression models [32] were applied to study
the relationship between HRQL and respiratory diseases,
controlling for the other potential determinants, estimat-
ing conditional medians of the response variables (PCS
and MCS). The quantile regression coefficients are inter-
preted as the ordinary regression ones and they indicate
the change in the dependent variable for every one unit
change (or category for nominal variables) in each covar-
iate [33]. As higher PCS and MCS scores are index of
better HRQL, a negative regression coefficient indicates
that an increase in the independent variable worsens
HRQL and vice versa.
Statistical analyses were performed using Stata Statis-
tical Software: Release 14.0 (www.stata.com).
Results
Sample characteristics
Out of 1046 subjects who went to the Verona clinic for
tests, 1012 (96.7%) correctly filled-in SF-36 question-
naire and 34 (3.3%) did not (6 did not fill it in com-
pletely, 28 did not answer more than three questions).
When compared to subjects with an available quality of
life questionnaire, subjects without SF-36 were similar
to the others, except for a lower education level (41.4%
vs 20.4%, p = 0.004), and age (47.1 vs. 44.0, p = 0.047)
(Table 1).
Out of 1012 subjects who filled-in the SF-36 question-
naire correctly, 328 (32.4%) were controls, 95 (9.4%) and
163 (16.1%) were NAR and AR respectively, 48 (4.7%)
suffered from CB, 126 (12.4%) and 224 (22.1%) were PA
and CA cases respectively, and 28 (2.8%) were COPD
cases (comorbidities among respiratory diseases are re-
ported in Additional file 2: Figures S1-S4).
The characteristics of the 1012 subjects included in
the main analyses are described in Table 2. Cases of
NAR and PA were prevalently females (61.1 and 57.9%
respectively), while cases of COPD were prevalently
males (75%; p = 0.021). With respect to the other cases
and controls, subjects suffering from COPD were older
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(52.2 years), had a lower educational status (35.7%) and
presented more often other non-respiratory comorbidi-
ties (50%). Controls, AR and past asthmatics were
mainly never smokers (52.8, 58.9 and 53.2% respect-
ively), while CB and COPD cases had the highest per-
centage of current smokers (37.5 and 32.1%). Cardiac
comorbidities were reported in higher percentages in
NAR (25.2%) and CB (22.9%) subjects than other cases
and controls. Non-respiratory comorbidities were more
frequent in COPD and CB subjects (50.0 and 41.7%
respectively).
PCS and MCS scores
The crude median PCS score of controls (55.1, IQD:
51.8–57.7) was higher than those of subjects suffering
from respiratory diseases (p < 0.001). In particular, the
physical score of NAR, AR and PA cases was respect-
ively 54.4, 53.9 and 54.2, while the scores of CA, CB and
COPD cases were the lowest of the sample (53.6, IQD:
48.8–56.3; 51.0, IQD: 47.4–55-8; 48.9, IQD: 45.9–56.8
respectively) (Fig. 2).
Controls and cases of PA had the highest crude me-
dian MCS score (52.3, IQD: 47.6–56.1; 52.4, IQD: 46.9–
55.9 respectively) followed by NAR, AR and CA (NAR
50.4, IQD: 45.2–56.4; AR 50.7, IQD: 45.1–55.0; CA 50.3,
IQD: 41.9–54.9) (Fig. 2). Subjects who suffered from CB
and COPD had the lowest MCS (CB 47.1, IQD: 41.7–
53.8; COPD 46.8, IQD 38.6–56.3 respectively). Median
MCS differed among controls and cases (p < 0.001).
The above-mentioned findings were confirmed when
the outcomes (PCS and MCS) were adjusted for possible
determinants and confounders (Table 3). In general, all
the subjects suffering from respiratory diseases showed
lower PCS scores than the controls. In particular, in sub-
jects who suffered from CB the median score was 3.8, in
current asthmatics 1.7 and COPD cases 5.6 statistically
significantly lower than in controls (Table 3). Both AR
and NAR did not show a significant difference in HRQL
with respect to controls.
Table 1 Characteristics of subjects who did and did not
complete the SF-36
SF-36
available
(n = 1012)
SF-36
not available
(n = 34)
p-value
Gender (female), n (%) 520 (51.4%) 21 (61.8%) 0.233
Age years, mean (sd) 43.96 (9.8) 47.11 (10.4) 0.047
BMI kg/m2, mean (sd) 24.8 (4.3) 24.5(4.2) 0.488
Education (low), n (%) 209 (20.7%) 14 (41.2%) 0.004
Smoking habits, n(%) 0.094
never smokers 500 (49.5%) 12 (35.3%)
past smokers 277 (27.4%) 15 (44.1%)
current smokers 233 (23.7%) 8 (22.2%)
Non-resp. comorbidities, n (%) 336 (33.3%) 9 (26.5%) 0.403
Cardiac comorbidities, n (%) 148 (14.7%) 5 (14.7%) 0.997
Phenotypesa, n (%) 0.448
controls 328 (32.4%) 15 (44.1%)
NAR 95 (9.4%) 6 (17.6%)
AR 163 (16.1%) 5 (14.7%)
CB 48 (4.7%) 1 (2.9%)
PA 126 (12.4%) 1 (2.9%)
CA 224 (22.1%) 5 (14.7%)
COPD 28 (2.8%) 1 (2.9%)
aNAR non-allergic rhinitis, AR allergic rhinitis, CB chronic bronchitis, PA past
asthma, CA current asthma, COPD chronic obstructive pulmonary disease
Table 2 Characteristics of casesa and controls who filled-in SF-36
Controls NAR AR CB PA CA COPD p-valueb
n (%) 328 (32.4%) 95 (9.5%) 163 (16.1%) 48 (4.7%) 126 (12.4%) 224 (22.1%) 28 (2.8%)
Gender (female), n (%) 168 (51.2) 58 (61.1) 79 (48.5) 26 (54.2) 73 (57.9) 109 (48.7) 7 (25.0) 0.021
Age years, mean (sd) 45.3 (9.6) 44.8 (9.7) 42.9 (10.7) 43.8 (9.6) 43.1 (9.4) 41.9 (9.4) 52.2 (8.5) < 0.001
BMI kg/m2, mean (sd) 25.0 (4.3) 24.3 (4.4) 24.3 (4.0) 24.8 (4.3) 24.9 (4.7) 24.8 (4.2) 25.8 (3.4) 0.231
Education (low), n (%) 78 (23.8) 24 (25.3) 25 (15.3) 18 (37.5) 15 (12.0) 39 (17.4) 10 (35.7) < 0.001
Smoking habits, n(%) < 0.001
never smokers 172 (52.8) 34 (35.8) 96 (58.9) 22 (45.8) 67 (53.2) 99 (44.2) 10 (35.7)
past smokers 98 (30.1) 33 (34.7) 38 (23.3) 8 (16.7) 31 (24.6) 60 (26.8) 9 (32.1)
current smokers 56 (17.2) 28 (29.8) 29 (17.8) 18 (37.5) 28 (22.2) 65 (29.0) 9 (32.1)
Non-resp. comorbidities, n (%) 74 (22.6) 45 (47.9) 55 (33.7) 20 (41.7) 47 (37.6) 81 (36.3) 14 (50.0) < 0.001
Cardiac comorbidities, n (%) 33 (10.2) 24 (25.2) 31 (19.0) 11 (22.9) 17 (13.6) 28 (12.5) 4 (14.3) 0.010
FEV1% predicted, mean (sd) 101.9(11.3) 100.9(12.6) 100.3 (12.0) 96.8(10.7) 98.9(12.4) 97.0 (12.3) 78.6 (15.5) < 0.001
aNAR non-allergic rhinitis, AR allergic rhinitis, CB other respiratory condition, PA past asthma, CA current asthma, COPD chronic obstructive pulmonary disease
bDifferences in categorical variables among phenotypes were tested by Pearson Chi-square test; differences in continuous variables among phenotypes were
tested using Kruskal-Wallis test
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The mental score was worse in CB (− 5.5, 95% Confi-
dence Interval-95%CI: − 8.7; − 2.2), current asthmatics
(− 2.2, 95%CI: -4.1; − 0.3) and COPD cases (− 4.6,
95%CI: -8.8; − 0.5) (Table 3), like in the case of PCS.
Moreover, the AR and NAR mental score did not differ
from the controls, similarly to the PCS.
Discussion
In our study, respiratory disorders seemed to exert an
influence on HRQL. Of importance, chronic diseases
conditioned not only the physical, but also the mental
health of affected subjects. This result is in line with
other studies [1, 29], where scores of individuals with
chronic conditions were lower (worse) than those of in-
dividuals not reporting any of the conditions studied.
Subjects suffering from COPD had the worse physical
and mental health scores. This result seems to be of par-
ticular interest since it derives from a general population
study. In their review, Joshi et al. [21], highlighted that
COPD causes disabling physical conditions and psycho-
logical distress similar to those of cancer. Many patients
with the most severe form of COPD suffer from depres-
sion, anxiety and panic, as a result of their physical im-
pairment and social isolation [34, 35]. Recent studies
have found that symptom burden of cancer and of se-
vere COPD are similar [21, 36, 37].
In this study, subjects suffering from CA had a lower
PCS and MCS than controls. In a European study of 864
asthmatic subjects conducted by Siroux et al. [38],
asthma-severity was a predictor of PCS score of SF-36
quality of life questionnaire, but not of the MCS one.
Ford et al. [39], in a US study conducted on 163,773
adults, found that people with CA have a worse HRQL
than past asthmatics (ever asthmatics without “current”
symptoms) and than subjects who have never suffered
from it. Legorreta et al. [40] reported that, among 5580
patients with asthma aged 14 to 65 years, the mean
scores for eight subscales of functional status were lower
than those reported by the general population. Further-
more, the authors found significant decreases in func-
tional status with increasing severity of asthma.
According to our hierarchical classification of respira-
tory diseases, a substantial percentage of subjects with CA
and PA also suffered from AR and NAR. We found that
rhinitis in subjects without asthma had no significant im-
pact on HRQL in our study. In fact, controls had similar
scores. This finding is not in line with other studies [7, 15]
Fig. 2 Physical and Mental SF-36 median scores and inter-quartile range by respiratory diseases
Table 3 Relationshipsa between HRQL (in terms of PCS and
MCS), respiratory diseases
PCS MCS
Coeff. (95%CI) Coeff. (95%CI)
Respiratory diseasesb (vs controls)
NAR 0.1 (−1.4;1.5) −0.8 (−3.3;1.7)
AR −0.8 (−2.0;0.4) − 1.5 (− 3.5;0.5)
CB − 3.8 (−5.7;-1.9) −5.5 (−8.7;-2.2)
Past asthma −0.7 (− 2.0;0.6) 0.7 (− 1.5;2.9)
Current asthma −1.7 (− 2.8;-0.6) −2.2 (−4.1;-0.3)
COPD −5.6 (− 8.1;-3.1) −4.6 (− 8.8;-0.5)
aassessed through quantile regression models (estimating conditional medians
of the response variable) considering PCS and MCS as dependent variables
and respiratory diseases and characteristics of the sample as independent
variables (adjusting for sex, age, BMI, educational level, smoking habits, non-
respiratory comorbidities, cardiac comorbidities, study cohort and calendar
period). Negative regression coefficients indicate a worsening in HRQL at an
increase of the independent variable and vice versa
bNAR non-allergic rhinitis, AR allergic rhinitis, CB chronic bronchitis, PA past
asthma, CA current asthma, COPD chronic obstructive pulmonary disease
All the values in bold are statistically significant (p<0.05)
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and ARIA guidelines [14]. This was probably due to the
fact that asthma was also present in patients with allergic
and non-allergic rhinitis in these studies.
The particularity of our survey was to study subjects
with NAR and AR without past or current asthma and
consequently, it was possible to assess the rhinitis effect
on HRQL, without the interference of any respiratory
comorbidity. Even if the physical and mental scores of
the subjects suffering from rhinitis were lower than con-
trols (except PCS for NAR cases), this difference was not
statistically significant and it can be hypothesized that it
is asthma that impairs HRQL, and not rhinitis alone.
Subjects suffering from CB had a lower physical and
mental health than subjects without any respiratory dis-
order. It is of interest that the decrease in PCS and MCS
is one of the highest among the considered respiratory
diseases (Fig. 2). This is a significant finding since there
are few studies [22] evaluating quality of life in subjects
with cough and phlegm but without bronchial obstruc-
tion and no one compared quality of life scores among
different respiratory diseases. Clinically, the presence of
respiratory symptoms among subjects with preserved
lung function may offer opportunity for interventions
potentially improving quality of life. Our findings could
also suggest that the exclusion of GOLD stage 0 from
the 2006 update might be re-considered. The association
found by Marcon et al. [26] of a reduced 6min walking
distance in subjects suffering from CB gives a potential
and partial explanation of our findings.
In a Serbian study [11], the authors demonstrated that
subjects suffering from CB and/or emphysema perceived
their health status as bad/ very bad, with respect to con-
trols. In another population-based survey conducted in
Finland [12], the people with CB lived a worse daily life
compared with the general population, and they had
poor physical health.
It is not well established whether the differences in
quality of life within subjects with respiratory diseases
and controls are stable over time. In a study on the sta-
bility of normative data for the SF-36 in a sample of the
general middle-aged Canadian population, mean SF-36
scores were found to change only slightly over three
years [41]. It is possible that the variation could be
greater in subjects with respiratory diseases, but to our
knowledge, no longitudinal studies comparing directly
healthy people and subjects with respiratory diseases
have been done.
This study was performed on a sample from the gen-
eral population of a single Italian centre, so the number
of subjects with a particular disease was sometimes
small: this fact could have somehow compromised the
generalizability of the study.
To our knowledge, this is the first population-based
study that investigates to what extent the most common
chronic respiratory disorders affect HRQL. Unlike previ-
ous studies, we were able to consider several diseases at
the same time by using a multicase-control design and a
hierarchical classification of disease status. Furthermore,
it is of note that this is the first study using SF-36 ques-
tionnaire in assessing simultaneously HRQL in a set of
different respiratory diseases. We found that subjects
who suffered from COPD, CA or CB had the poorest
HRQL. On the whole, these findings emphasise that,
even at the mild level of severity that is common in the
general population, COPD and asthma have a significant
impact on HRQL. Moreover, our data indicate that also
CB, with lower impact on DALYs in comparison to
COPD or CA [4] is not a trivial condition. It derives that
clinicians should also carefully consider CB in relation
to HRQL of these patients.
Moreover, our results highlights that not only physical
but also psychological dimension of subjects with
chronic respiratory diseases should be considered in
clinical practice.
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